Hazer Khalifa

Dr. Hazer Khalifa

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in Psychoactives
Verified
Journal Article
Open access
PDF file
HKHazer Khalifa
Hazer Khalifa
EHEmily Hibbert
Emily Hibbert
NGNatalie Gauci
Natalie Gauci
APAlison Poulton
Alison Poulton
Dexamphetamine (DEX) is widely used in treatments, but concerns persist about its potential for addiction. This review aimed to assess the risks of DEX addiction by examining the existing literature. Originally planned as a systematic review, it was adjusted to a narrative review due to a lack of qualifying studies. A search of the literature on addiction to DEX was conducted on three databases including PubMed, Scopus, and Embase. Seven articles consisting of three reviews and four papers with original data were identified and reviewed. In total, four poorly documented cases of possible DEX addiction were found. The commonly cited papers on prescription DEX addiction did not hold up to scrutiny. Overall, the evidence that DEX is addictive is limited and inconclusive, highlighting the need for more rigorous research to clarify its true addiction risk.

26 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HKHazer Khalifa
Hazer Khalifa
EHEmily Hibbert
Emily Hibbert
NGNatalie Gauci
Natalie Gauci
APAlison Poulton
Alison Poulton
Dexamphetamine (DEX) is widely used in treatments, but concerns persist about its potential for addiction. This review aimed to assess the risks of DEX dependence by examining existing literature. Originally planned as a systematic review, it was adjusted due to a lack of qualifying studies. Of seven cohort and case studies reviewed, only four poorly documented cases of possible DEX addiction were found. Commonly cited papers on prescription amphetamine addiction did not hold up to scrutiny. Overall, the evidence that DEX is addictive is limited and inconclusive, highlighting the need for more rigorous research to clarify its true addiction risk.

18 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
APAntoinette Poulton
Antoinette Poulton
NGNatalie Gauci
Natalie Gauci
HKHazer Khalifa
Hazer Khalifa
EHEmily Hibbert
Emily Hibbert
APAlison Poulton
Alison Poulton
Background: Amphetamines increase dopamine levels in mid-brain regions which, in turn, impact top-down executive function. Repeated exposure is linked to substance use disorders. Nonetheless, amphetamines are used to manage attention-deficit/hyperactivity disorder (ADHD) and eating-related disorders. In ADHD, amphetamines upregulate a system characterised by low dopaminergic tone, assisting to improve executive function. A similar process might be at play with eating disorders; however, the effect of amphetamine treatment on executive function in this case has not been thoroughly considered. Methods: Participants (N = 52, Mage = 47.06, SD = 12.29) with a body mass index of 25–60 were randomised to treatment (6-week dexamphetamine titration) or control (placebo) groups. They completed an executive function measure—Barkley Deficits in Executive Functioning Scale (BDEFS-SF)—and response inhibition task—Stop-Signal Task (SST)—at Baseline, throughout titration, at Maintenance, and at Follow-up. Mixed effects models examined whether BDEFS-SF score or the SST variable, stop-signal reaction time (SSRT), changed across sessions as a function of treatment. Results: There was no effect of group (p = 0.440), but an effect of session (p = 0.024) on BDEFS-SF, with scores at Time 2 (p = 0.011, 95% CI [0.47, 3.49]) and Maintenance (p = 0.022, 95% CI [−4.89, −0.39]), respectively, higher and lower than other timepoints. There was no group by session interaction (p = 0.659). R2 (conditional) = 0.74; ICC = 0.73. There was an effect of group (p = 0.039) and session (p < 0.001) on SSRT, but no interaction (p = 0.707). Baseline SSRT was significantly longer than the mean of all subsequent timepoints (p < 0.001, 95% CI [16.29, 33.84]). R2 (conditional) = 0.47; ICC = 0.39. Conclusions: There was no discernible impact of amphetamine treatment for obesity on executive function. Our results suggest some variation related to sample size and/or practice effects. Thus, while treatment appears unlikely to render individuals susceptible to substance use disorders, parallels with ADHD might be overstated.